A cannabis compound reduced bladder inflammation and pain in mice better than the standard treatment | Research

The takeaway

Beta-caryophyllene, a CB2 receptor agonist found in cannabis, reduced bladder inflammation and pain in a mouse model of interstitial cystitis, performing comparably to a synthetic CB2 agonist and superior to the FDA-approved treatment DMSO.

Urologists, interstitial cystitis patients, and researchers studying CB2-targeted anti-inflammatory therapies.

Better than FDA-approved treatment

What the researchers found

Both beta-caryophyllene (BCP) and the synthetic CB2 agonist HU308 significantly reduced leukocyte adhesion in bladder venules and improved capillary perfusion when instilled directly into the bladder. BCP was comparable to HU308 and superior to DMSO (the FDA-approved treatment). Oral BCP also reduced inflammation and mechanical pain.

Why it matters

Interstitial cystitis has limited treatment options and current therapies are often inadequate. BCP is a natural compound with GRAS (Generally Regarded as Safe) status found in common foods, making it a particularly accessible potential treatment candidate.

The numbers in context

BCP significantly reduced leukocyte adhesion in bladder venules. BCP improved capillary perfusion. Effects comparable to synthetic CB2 agonist HU308. Superior to DMSO (FDA-approved treatment). Oral BCP also effective for inflammation and pain.

How the study worked

Animal study using LPS-induced interstitial cystitis in mice. Intravital microscopy measured bladder inflammation. Behavioral testing assessed pain. Compared BCP, synthetic CB2 agonist HU308, and DMSO (standard treatment).

What this study cannot tell us

Mouse model using LPS-induced cystitis may not fully represent the complex human condition. Single study without dose-response optimization. Translation from intravital microscopy endpoints to clinical outcomes is uncertain.

How to read the evidence

Rated preliminary because this is a single animal study, despite promising comparisons to an approved treatment.

When this study was published

Published in 2019.

The bigger picture

BCP is found in black pepper, cloves, hops, and cannabis. If a dietary compound already classified as safe can outperform the standard treatment for interstitial cystitis, it could offer a low-risk therapeutic option for a condition that affects millions.

Questions still open

Would BCP work in human interstitial cystitis? What is the optimal route and dose for clinical use? Could BCP be combined with existing treatments for additive benefit?

Common questions

What is beta-caryophyllene?

A natural terpene found in cannabis, black pepper, cloves, and other plants. It activates CB2 cannabinoid receptors without psychoactive effects and has GRAS (Generally Regarded as Safe) status as a food additive.

Could this help interstitial cystitis patients?

In mice, it outperformed the current standard treatment. Human studies would be needed to confirm this, but the compound's existing safety profile makes it a promising candidate for clinical trials.

Read the original research

Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice.

Molecules (Basel, Switzerland), 24(23)

View on PubMed ↗Publisher’s paper ↗

Citation

Berger, Geraint; Arora, Nipun; Burkovskiy, Ian; Xia, Yanfang; Chinnadurai, Anu; Westhofen, Robert; Hagn, Georg; Cox, Ashley; Kelly, Melanie; Zhou, Juan; Lehmann, Christian. (2019). Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice.. Molecules (Basel, Switzerland), 24(23). https://doi.org/10.3390/molecules24234239